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Resistance to Endotoxin Shock and Reduced
Dissemination of Gram-Negative Bacteria
in CD14-Deficient Mice
Alain Haziot,* Enza Ferrero,*§ Frank KoÈ ntgen,²‖ remain unclear. Although several receptors for endo-
toxin/LPS have been recently identified by means ofNaoki Hijiya,* Shunsuke Yamamoto,³
Jack Silver,* Colin L. Stewart,² cellular studies (Lei and Morrison, 1988; Bright et al.,
1990; Lei et al., 1991; Hampton et al., 1991; Wright etand Sanna M. Goyert*
*Division of Molecular Medicine al., 1990; Ingalls and Golenbock, 1995), the relative role
of each of them in the development of endotoxin shockNorth Shore University Hospital
Cornell University Medical College in vivo is unknown. Amongthese receptors isa glycopro-
tein known as CD14, which is expressed on monocytesManhasset, New York 11030
²Roche Institute for Molecular Biology and neutrophils as a glycosylphosphatidylinositol (GPI)-
anchored molecule (Goyert et al., 1988, Haziot et al.,340 Kingsland Avenue
Nutley, New Jersey 07110 1988, 1993a). The demonstration that transgenic mice
overexpressing CD14 are hypersensitive to LPS has³Department of Pathology
Oita Medical University suggested that CD14 may also play an important role
in the in vivo response to endotoxin (Ferrero et al., 1993).Hasama-machi, Oita 879-55
Japan To assess fully the importance of CD14 and other recep-
tors in the development of endotoxin shock in vivo,
CD14-deficient mice were generated by targeted disrup-
tion of the CD14 gene in murine embryonic stem (ES)Summary
cells and examined for their sensitivity to endotoxin/
LPS and to Gram-negative bacteria.Endotoxin shock is the result of activation of the im-
mune system by endotoxin/LPS, a component of
ResultsGram-negative bacteria. CD14, a GPI-anchored gly-
coprotein expressed strongly by monocyte/macro-
Production of CD14-Deficient Micephages, is one of several receptors for endotoxin/LPS.
CD14-deficient mice were produced by homologous re-The role of CD14 in bacterial-induced and LPS-in-
combination in ES cells (Thomas and Capecchi, 1987;duced shock was tested in CD14-deficient mice pro-
Stewart, 1993). The gene was disrupted by removal ofduced by gene targeting in embryonic stem cells.
a 272 bp segment including the CD14 initiation codonCD14-deficient mice were found to be highly resistant
at the 39 end of exon 1, the 97 bp intron, and 172 bp ofto shock induced by either live Gram-negative bacteria
the coding region in exon 2 and replacement with aor LPS; however, at very high concentrations of LPS
neor gene (containing its own stop codon but withoutor bacteria, responses through non-CD14 receptors
polyadenylation signals); this replacement resulted in acould be detected. Surprisingly, CD14-deficient mice
frame shift in the remaining CD14 sequence (Figure 1A).also showed dramatically reduced levels of bacter-
After electroporation of W9.5 ES cells, cells from cloneemia, suggesting an unexpected role for CD14 in the
E11 carrying the disrupted CD14 gene were injected intodissemination of Gram-negative bacteria.
C57BL/6 mice blastocysts. Male chimeras were bred
with C57BL/6 mice and the offspring were interbred to
produce homozygous CD14-deficient mice. The disrup-Introduction
tion of the CD14 gene was confirmed by Southern blot
hybridization. As shown in Figure 1B, a larger CD14 geneActivation of the immune system by Gram-negative bac-
fragment was detected in mutant animals. The changeteria, its products, or both can result in a cascade of
in size is in agreement with the expected changes pro-events leading to endotoxin shock, a situation where
duced by the 272 bp deletion and the neo cassettelarge amounts of cytokines such as tumor necrosis fac-
insertion. Disruption of the CD14 gene results in loss oftor-a (TNFa) and interleukin-6 (IL-6), as well as other
expression of CD14, confirmed by staining of peritonealinflammatory mediators are produced (Morrison and
macrophages with a monoclonal anti-murine CD14 anti-Ryan, 1987; Bone, 1991; Tracey and Cerami, 1994; Akira
body (Figure 1C). CD14-deficient mice have no obviouset al., 1993). If unaltered, these events frequently lead
abnormalities and are fertile and healthy (>1 year) in ato death. Endotoxin/lipopolysaccharide (LPS), a compo-
clean, controlled (laminar-flow) environment.nent of the cell wall of Gram-negative bacteria, was
identified many years ago as a major mediator of shock
induced by Gram-negative bacteria (Rietschel et al., Resistance to Lethal Challenge with Endotoxin/LPS
1994); however, the receptors and pathways of respon- in CD14-Deficient Mice
siveness utilized in vivo to trigger the massive cellular To assess the function of CD14 in the responses to LPS
and humoral responses observed in endotoxin shock in vivo, CD14-deficient mice were tested in two models
of endotoxic shock. In the first model, CD14-deficient
and control mice were treated with LPS alone (Salmo-§Current address: Department of Genetics, Biology and Medical
nella minnesota) given intraperitoneally at a dose thatChemistry, University of Torino, Torino, Italy.
produced 100% lethality in control mice (LD100) or, at 10‖ Current address: The Walter and Eliza Hall Institute of Medical
Research, The Royal Melbourne Hospital, Victoria, Australia. times this dose. As shown in Figure 2, 100% of the
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Figure 1. Disruption of the CD14 Gene by
Homologous Recombination
(A) Map of the CD14 SstI genomic fragment,
of the targeting construct, and of the pre-
dicted disrupted gene. Closed boxes denote
the CD14 exons. The first exon contains the
ATG translation start site. The neo box repre-
sents the pgk-driven poly(A)2 neo gene. The
tk box represents the herpes simplex virus±
thymidine kinase gene. The thick line repre-
sents genomic DNA sequences; the thin line
represents plasmid DNA sequences. The re-
striction enzyme abbreviations are as follows:
X, XhoI; Sa, SalI; S, SstI; E, EcoRI; B, BamHI;
Nc, NcoI; No, NotI. The 39 flanking SstI±EcoRI
CD14 genomic fragment was used as a probe
in Southern blot hybridizations.
(B) Southern blot analysis of mouse tail DNA.
Genomic DNA was isolated from mouse tails,
digested with EcoRI, electrophoresed and
hybridized with the CD14 genomic SstI±
EcoRI probe. Lane 1, heterozygous; lane 2,
wild-type; lane 3, homozygous mutation. Size
markers are indicated on the left.
(C) Expression of CD14 by peritoneal macro-
phages of control (top) and CD14-deficient
(bottom) mice. Peritoneal macrophages were
recovered by peritoneal lavage, blocked with
a human Fc fragment (5 mg/5 3 105 cells;
Capell, West Chester, Pennsylvania), and
stained by indirect immunofluorescence with
the anti-mouse CD14 monoclonal antibody
rmC5-3 (Matsuura et al., 1994) or an isotype-
matched control (IgG1) followed by fluores-
cein isothiocyanate±labeled goat-anti-rat IgG
(Boehringer Mannheim, Indianapolis, Indi-
ana). Analysis was performed on a Profile
(Coulter) cytofluorometer.
CD14-deficient mice injected with either dose of LPS
survived, while 100% of the control mice died. In addi-
tion, CD14-deficient mice injected with an LD100 (20 mg
LPS/kg) showed no obvious outward signs of response
to endotoxin; however, when injected with 10 times the
LD100 (200 mg LPS/kg) some of the mice showed minor
signs similar to those associated with endotoxemia,
such as eye exudate and diarrhea, during the first 24 hr.
During this period, their condition and activity remained
normal and none died.
The second model of endotoxic shock consisted of
sensitizing mice to the effects of LPS with D-galactos-
amine, an inhibitor of hepatocyte metabolism (Galanos
et al., 1979; Decker and Keppler, 1974; Wendel, 1990).
This reagent makes mice hypersensitive to low levels
of shock-inducing cytokines (Lehmann et al., 1987; Ga-
lanos and Freudenberg, 1993). As was observed in the
previous model, 100% (5 of 5) of theCD14-deficient mice
survived an LD100 (2 mg/kg) of LPS (Table 1). However, at
higher doses of LPS (10 mg/kg), the CD14-deficient mice
Figure 2. Lethality Induced by LPS in CD14-Deficient Miceshowed some responsiveness, and at 10 times the LD100
Mice (5 per group) were injected intraperitoneally with the indicatedall the CD14-deficient mice died (Table 1). To rule out
doses of LPS from S. minnesota in 0.2 ml nonpyrogenic saline.the possibility that this residual response to LPS was
LD100 doses of LPS were predetermined in separate experiments.
due to the 1% contamination of the LPS preparation by All deaths occurred within 72 hr. A second similar experiment gave
bacterial proteins, a second preparation of LPS (E. coli identical results. Triangles, CD14-deficient 20 mg/kg; squares,
CD14-deficient 200 mg/kg; circles, control 20 mg/kg.K235) that contained only 0.0008% of contaminating
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Table 1. Survival of CD14-Deficient and Control Mice after Treatment with D-Galactosamine and LPS
LPS (S. Minnesota) LPS (E. Coli (K235)
Mice 2 mg/kg 10 mg/kg 20 mg/kg 0.5 mg/kg 1 mg/kg 5 mg/kg
Control 0/5 ND ND 1/5 ND ND
CD14-deficient 5/5 2/5 0/5 4/5 3/5 0/5
Mice were injected intraperitoneally with the indicated doses of LPS from S. minnesota wild-type or low-protein LPS from E. coli K235 and with
D-galactosamine (0.6 g/kg) in 0.2 ml nonpyrogenicsaline. LD100 doses of LPS and the sensitizing dose of D-galactosamine were predetermined in
separate experiments. All deaths occured within 24 hr.
protein (Hogan and Vogel, 1988) was used. Very similar monocytes to respond to LPS through the CD14 path-
results were obtained with this low protein preparation way, peripheral blood mononuclear cells (PBMCs) from
of LPS (Table 1), indicating that the lethality observed CD14-deficient mice were stimulated with up to 10 mg/
at high LPS concentrations was due to the LPS and not ml of LPS in the presence of 1% autologous serum. As
a contaminant. can be seen in Figure 4A, PBMCs from CD14-deficient
To confirm that the CD14-deficient mice show a nor- mice did not secrete any detectable TNFa even when
mal sensitivity to other inflammatory mediators, their exposed to LPS at concentrationsof 100 ng/ml, whereas
sensitivity to platelet-activating factor (PAF), an inflam- control mice showed a strong response even at 1 ng/
matory mediator that acts distally to the LPS±CD14 in- ml. Only at an LPS concentration of 1 mg/ml did the
teraction, was examined. In a PAF-induced lethal shock CD14-deficient monocytes show a detectable TNFa re-
model (Sun and Hsueh, 1991), CD14-deficient and con- sponse and, even at that concentration of LPS, the re-
trol mice both showed a similar sensitivity and died at sponse was less than that observed for normal mono-
similar rates (data not shown). cytes at an LPS concentration of 1 ng/ml (Figure 4A).
Since CD14-deficient mice could nevertheless pro-
Cytokine Responses of CD14-Deficient duce significant amounts of IL-6 at high doses of LPS
Mice to Endotoxin/LPS (see Figure 3B), the ability of high concentrations of LPS
To confirm the low responsiveness of CD14-deficient to induce IL-6 production by blood monocytes from
mice to LPS, the serum concentrations of TNFa and IL-6 these mice was examined.As shown inFigure 4B, mono-
were measured. These inflammatory cytokines normally cytes from CD14-deficient mice produced no IL-6 when
greatly increase in mice treated with LPS. As seen in stimulated with LPS at concentrations up to 1 mg/ml
Figure 3A, virtually no secreted TNFa was observed in and only a very small amount of IL-6 was secreted at
serum from CD14-deficient mice injected with LPS (20 10 mg LPS/ml. This suggests that the IL-6 produced in
mg/kg), in contrast with the high levels secreted by con- vivo by CD14-deficient mice injected with high doses
trol mice treated with the same dose. Furthermore, of LPS (see Figure 3B) is derived from cells distinct from
CD14-deficient mice injected with a 10-fold higher dose blood monocytes.
of LPS (200 mg/kg) produced no additional TNFa. Simi-
larly, at a dose of LPS of 20 mg/kg, negligible amounts
Identification of a Novel Pathway for LPSof IL-6 were detected in the serum of CD14-deficient
Activation of Monocytesmice, in contrast with the strong IL-6 response observed
Previous studies on cells that normally do not expressin control mice that received the same treatment; how-
CD14 on the cell surface, such as endothelial cells, haveever, at a 10-fold higher dose of LPS, a substantial IL-6
revealed a secondary pathway of LPS activation (Freyresponse could be detected in CD14-deficient mice, al-
et al., 1992; Haziot et al., 1993b; Pugin et al., 1993). Thisthough this represented less than 70% of the response
pathway utilizes a soluble form of the CD14 receptor,of normal mice injected with 10 times less LPS (Fig-
either natural or recombinant, as a coligand in conjunc-ure 3B).
tion with LPS (Frey et al., 1992; Haziot et al., 1993b).
Binding of this sCD14±LPS complex to an, as yet,Resistance of CD14-Deficient Monocytes
unknown receptor leads to activation. To determineto an Endotoxin/LPS Challenge
whether monocytes have the ability to respond to LPSTo confirm that the attenuated response of CD14-defi-
cient mice to LPS was due to the reduced ability of via a pathway analogous to that of endothelial cells in
Figure 3. Serum Concentrations of Cyto-
kines in CD14-Deficient Mice Injected with
LPS
Mice (3 per group) were injected intraperito-
neally with 20 or 200 mg/kg LPS (S. minne-
sota) and were bled from the tail vein at the
times indicated. TNFa (A) and IL-6 (B) con-
centrationswere determined by bioassay and
ELISA, respectively. Results are represented
as mean value 6 SEM in each group. Trian-
gles, CD14-deficient 20 mg/kg; squares,
CD14-deficient 200 mg/kg; circles, control 20
mg/kg.
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Figure 4. Production of Cytokines Induced
by LPS from CD14-Negative and Control
PBMC
Cells were isolated by density gradient cen-
trifugation and incubated with various con-
centrations of LPS. TNFa (A) and IL-6 (B) con-
centrations were determinedby bioassay and
ELISA, respectively. Closed squares, CD14-
deficient; open circles, control.
which sCD14 is utilized as a coligand, the effects of control mice were treated with an inoculum of Esche-
richia coli 0111:B4 (5 3 106 cfu) that was lethal to controlLPS in the presence of rsCD14 were analyzed in CD14-
negative monocytes obtained from the CD14-deficient mice. As can be seen in Figure 6A, at this dose of Gram-
negative bacteria the normal controls died within 36 hr,mice. As shown in Figure 5A, PBMC from CD14-defi-
cient mice respond poorly, if at all, to LPS, even at whereas all of the CD14-deficient mice not only survived
but showed no sign of shock. When the dose of E. coliconcentrations of 1 mg/ml in the presence of 1% autolo-
gous serum. However, when these monocytes are incu- was increased 6-fold (30 3 106 cfu) the CD14-deficient
mice appeared healthy and alert for a period of 12±16bated with LPS in the presence of rsCD14 (20 mg/ml),
TNFa secretion becomes easily detectable at an LPS hr before their condition deteriorated and they began to
die. In contrast, the control mice were strongly affectedconcentration of 100 ng/ml and appears to peak at an
LPS concentration of 10 mg/ml. Activation via this path- within 4 hr following the injection of bacteria and showed
typical signs of endotoxic shock, such as diarrhea, eyeway also occurs at a rsCD14 concentration of 2.5 ng/ml,
a concentration that approximates physiologic serum exudate, weakness, and ruffled fur. All of the control
mice died within 24 hr at this increased dose of E. coli.levels of sCD14 in humans (Grunwald et al., 1992), al-
though the amount of TNFa release is about 50% less To determine whether the decreased sensitivity of
CD14-deficient mice to shock induced by Gram-nega-(data not shown).
The activation of CD14-negative monocytes via the tive bacteria is associated with reduced levels of endo-
toxin shock-related cytokines, the levels of TNFa andsCD14±LPS pathway results not only in the release of
TNFa but also in the production of IL-1b. As shown in IL-6 in the serum of both the control and CD14-deficient
mice after the injection of Gram-negative bacteria wereFigure 5B, CD14-negative macrophages produce signif-
icant amounts of IL-1b when incubated with rsCD14 (20 determined. Injection (intraperitoneally) of CD14-defi-
mg/ml) and LPS (100 ng/ml), whereas in the absence of cient mice with the lethal dose for the controls (5 3 106
rsCD14, CD14-negative macrophages produce no sig- E. coli) showed little or no cytokine production (data not
nificant levels of IL-1b even at LPS concentrations of shown) similar to what was previously observed in the
10 mg/ml. Control macrophages, which can also be acti- response to LPS (see Figure 3). When the dose of bacte-
vated by LPS via the conventional membrane±CD14 re- ria was increased to a lethal dose for the CD14-deficient
ceptor, are capable of producing significant amounts of mice (3 3 107), the TNFa response after 7 hr of infection
IL-1b even at an LPS concentration of 1 ng/ml. was 10-fold lower than in control mice (Figure 6B). Simi-
larly, the IL-6 serum concentrations after infection were
48-fold lower in CD14-deficient mice than in control ani-
mals (Figure 6C). Serum concentrations of IL-1 wereResistance of CD14-Deficient Mice to a Lethal
Challenge of Gram-Negative Bacteria also depressed in infected CD14-deficient mice (data
not shown). These low levels of cytokines as comparedTo assess similarly the role of CD14 in the response
to intact Gram-negative bacteria, CD14-deficient and with the control mice correlate with the lack of gross
Figure 5. Production of Cytokines Induced
by sCD14 and LPS from CD14-Negative and
Control PBMC
PBMC (A) and thioglycollate-elicited perito-
neal macrophages (B) from C57BL/6J and
CD14-deficient mice were incubated with
rsCD14 (20 mg/ml) and various concentra-
tions of LPS (Haziot et al., 1995) in medium
supplemented with 1% autologous serum.
TNFa concentrations (A) in cell-free superna-
tants were determined by bioassay (Haziot
et al., 1993a) and IL-1b production (B) was
determined in cell lysates (Kitchens et al.,
1992) by ELISA. Open squares, CD14-defi-
cient; closed squares, CD14-deficient with
added rsCD14; open circles, control C57BL/
6J. Results shown are representative of two
independent experiments.
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Figure 6. Resistance of CD14-Deficient Mice to Bacterially Induced Shock
(A) Lethality after Gram-negative infection. Mice were infected intraperitoneally with the indicated number of cfu of E. coli 0111:B4. All deaths
occurred within 48 hr following infection and the condition of the surviving mice was monitored for 21 days. Numbers above the bars indicate
number of survivors/number of mice in group.
(B, C) Serum concentrations of TNFa and IL-6 in E. coli-infected mice. Mice were injected intraperitoneally with E. coli (n 5 4) and cytokines
were measured in peripheral blood 7 hr after injection. TNFa and IL-6 were measured by bioassay (2) and by ELISA (Endogen), respectively.
Results are represented as mean 6 SEM in each group. p < 0.05 (Mann-Whitney test).
physiological symptoms. When the mice were infected E. coli in the blood 7 hr after infection. As seen in Figure
8A, CD14-deficient mice infected with a dose of E. coliintravenously, rather than intraperitoneally, with a dose
that was lethal to the control mice (5 3 106 cfu perof live bacteria that was lethal for the CD14-deficient
mouse) had a 27-fold lower level of bacteria in the bloodmice, a similar reduction incytokine levels was observed
than control mice. Similarly, when a dose that was lethalin theCD14-deficient mice (Figure 7).Under these condi-
to both control and CD14-deficient mice was used (3 3tions, TNFa produced by the control mice peaked at 90
107 cfu per mouse) (Figure 8B), 35-fold fewer bacteriamin, at which time it was completely absent in the CD14-
were found in the blood of the CD14-deficient mice thandeficient mice; however, by 4 hr, at a time when control
in control mice. The number of live bacteria in the lungsmice no longer expressed TNFa, the CD14-deficient
of mice injected with 3 3 107 Gram-negative bacteriamice began to express low levels of TNFa and this ex-
was also similarly reduced in CD14-deficient mice (Fig-pression increased with time. Similar analyses of IL-6
ure 8C). Thus, the inability to activate monocytesexpression after intravenous injection of live bacteria
through CD14 in CD14-deficient mice is associated withshowed a very low level of IL-6 expression by the CD14-
a greatly reduced bacteremia and bacterial load in or-deficient mice after 3 hr, at which time the expression
gans such as the lung.of IL-6 in the control mice peaked. As time progressed,
the expression of IL-6 by the CD14-deficient mice in-
Discussioncreased.
The studies described here were designed to assess
the role of the monocyte/neutrophil cell surface marker,Resistance of CD14-Deficient Mice
CD14, in shock induced by either endotoxin/LPS orto Bacterial Spread
Gram-negative bacteria. A number of receptors for LPSSince bacteremia is often used as a measurement of
other than CD14 have previously been described (Leithe severity of sepsis, the CD14-deficient and control
and Morrison, 1988; Bright et al., 1990; Lei et al., 1991;mice were examined with respect to theamount of viable
Hampton et al., 1991; Wright et al., 1990; Ingalls and
Golenbock, 1995), although the relative role of these in
the induction of endotoxin/LPS shock has been unclear.
The use of CD14-deficient mice produced by the tech-
niques of homologous recombination facilitated these
studies and made it possible to draw a number of impor-
tant and unequivocal conclusions regarding the role of
CD14. It was observed that the absence of CD14 is
sufficient to dramatically attenuate most of the effects
of LPS in these mice; CD14-deficient mice are highly
insensitive to endotoxin/LPS-induced shock as deter-
mined by LPS-induced mortality (Figure 2). Furthermore,
at an endotoxin/LPS dose that kills 100% of normal
mice, CD14-deficient mice produce negligible amountsFigure 7. Serum Concentrations of TNFa and IL-6 in E. coli-Infected
of TNFa and IL-6 (Figures 3A and 3B), known mediatorsMice
of endotoxin shock (Tracey and Cerami, 1994; Akira etMice were injected intravenously with E. coli (3 3 107 cfu/mouse,
al., 1993).n 5 3) and cytokines were measured in peripheral blood as de-
With regard to shock induced by Gram-negative bac-scribed above. Closed squares, CD14-deficient; open circles,
control. teria, the remarkable survival of CD14-deficient mice
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Figure 8. Blood and Organ Counts of Bacteria in E. coli-Infected Mice
Bacterial counts were determined 7 hr after intraperitoneal infection with (A) 5 3 106 cfu (4 mice per group), (B) 3 3 107 cfu (4 mice per group),
and (C) 3 3 107 cfu (3 mice per group) of E. coli 0111:B4. The number of cfu in blood (A and B) and lung (C) were determined as described
in Experimental Procedures. Results are represented as mean 6 SEM in each group. p < 0.05 (Mann-Whitney test).
with no evidence of symptoms relating to shock when not normally express CD14 on the cell surface, such as
injected with an inoculum of E. coli that is lethal to endothelial cells (Haziot et al., 1993b). However, there
control mice (Figure 6A) indicates that CD14 also plays appear to be several major differences between the two;
a major role in mediating this fatal response. whereas endothelial cells can be activated in the pres-
Nevertheless, several observations of the response ence of soluble CD14 using concentrationsof LPS below
of CD14-deficient mice to LPS suggest the existence of 1 ng/ml (Haziot et al., 1995), the CD14-negative mono-
additional LPS receptors that may play a role, although cytes need 100 times this concentration (Figures 4A and
minor, in inducing endotoxic shock. These include the 4B). Second, whereas sCD14 is the only serum factor
following: first, the observation of a residual TNFa re- required for the response of endothelial cells to high
sponse to LPS in CD14-deficient mice (Figure 3A); sec- concentrations of LPS in serum-free conditions (Haziot
ond, the LPS-induced lethality observed in D-galactos- et al., 1993b), CD14-negative monocytes need other se-
amine±treated CD14-deficient mice (Table 1), an agent rum factors in addition to sCD14 to be able to utilize
that sensitizes mice to low levels of inflammatory cyto- the sCD14 pathway of responsiveness (data not shown).
kines such as TNFa (Galanos and Freudenberg, 1993); These differences suggest that the LPS±sCD14 path-
and third, the observation that at high doses of en- ways utilized by these two cell types may employ differ-
dotoxin/LPS CD14-deficient mice produce substantial ent receptors or intracellular signaling mechanisms,
amounts of IL-6 (Figure 3B). In the latter case, the recep- or both.
tors responsible for the induction of IL-6 secretion must In addition to documenting the preminent role of CD14
reside on cellsother than monocytes, since blood mono- in the development of endotoxic/LPS shock following
cytes do not appear to be the source of this IL-6 produc- exposure to LPS or Gram-negative bacteria, these stud-
tion (Figure 4B). Furthermore, the IL-6 response by these ies revealed an unexpected and prominent role for CD14
receptors appears to be independent of TNFa because, in bacterial dissemination (Figure 8). The decreased pro-
in contrast with IL-6, which increases dramatically at duction in CD14-deficient mice of cytokines such as
high endotoxin/LPS concentrations (Figure 3B), there is IL-1 and TNFa, proteins that are known to promote the
no similar increase in TNFa serum concentrations at growth and invasiveness of pathogenic Gram-negative
high endotoxin/LPS concentrations (Figure 3A). bacteria (Porat et al., 1991; Luo et al., 1993), could be
The observation of the effects of a high inoculum of responsible for this effect. Alternatively, elimination of
E. coli on CD14-deficient mice similarly suggests the
the inhibitory effects of endotoxin on bacterial clearance
existence of other receptors that result in the delayed
mechanisms, such as those that have been described
gradual expression of TNFa and IL-6 and eventually lead
in LPS-treated rabbits (Koch et al., 1993), owing to the
to death (Figures 6 and 7). The delayed expression of
inability of monocytes to be ªtriggeredº by LPS throughcytokines by the CD14-deficient mice was accompanied
CD14, may be responsible for the reduced dissemina-by a delay in the appearance of gross symptoms, which
tion of bacteria in CD14-deficient mice. In any event,occurred 12 to 16 hr after bacterial injection, in contrast
the reduced bacteremia observed in infected CD14-defi-with the control mice, which showed classical shock
cient mice suggests that reagents designed to block orsymptoms after only 4 hr. Whether the receptors re-
neutralize CD14 on the surface of monocytes may notsponsible for these effects in the CD14-deficient mice
only be effective in preventing endotoxic shock (Haziotresulting in death are specific for endotoxin/LPS or
et al., 1995), but may also be equally effective in pre-for some other bacterial component is unclear at the
venting the rapid dissemination of bacteria in Gram-moment.
negative infections.Finally, the observation that monocytes from CD14-
deficient mice can respond to high doses of LPS in the
Experimental Procedurespresence of sCD14 (Figure 5) suggests the existence
of yet another pathway for LPS-induced activation of Construction of the Targeting Vector
monocytes acting by an, as yet, unknown mechanism. A 12 kb SstI mouse genomic fragment containing the murine CD14
This novel pathway of responsiveness to LPS is reminis- gene was isolated from a 129/Sv library (gift of Dr. R. Kinloch, Roche
Institute for Molecular Biology, Nutley, New Jersey) and subclonedcent of the pathway used by other cell types that do
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into pUC18. This plasmid was cut with NcoI±NotI, removing a 272 serum-free baculovirus expression system (Haziot et al., 1994) and
bp fragment of the CD14 gene, and blunt-ended. In place of the LPS (Salmonella minnesota) wereadded at concentrations indicated
CD14 fragment, a 1.3 kb blunt-ended EcoRI±BamHI fragment from in the text. After 4 hr incubation at 378C in 5% CO2, the cell-free
pKJ1 (Li et al., 1992) containing a poly(A)2 neor gene under the supernatant was collected and assayed for cytokine content.
control of the phosphoglycerate kinase (pgk) promoter. A recombi- Peritoneal macrophages were collected 4 days after intraperito-
nant clone bearing the CD14 gene and neo in the same orientation neal injection of 3 ml of a 3% thioglycollate medium (Difco Labora-
was isolated. Finally, a 2.2 kb XhoI fragment from pBluescript KS±tk, tories, Detroit, Michigan) by peritoneal lavage with RPMI. After one
containing the HSV thymidine kinase (tk) gene under the control of wash in RPMI, cells were plated at 2 3 106/ml in RPMI±HEPES
the pgk promoter, was inserted into the SalI site of the CD14±neo supplemented with 1% autologous serum in 24-well plates (Becton
construct, in the opposite orientation with respect to CD14±neo Dickinson, Lincoln Park, New Jersey) and incubated for 3 hr at 378C
(Figure 1). in 5% CO2. Nonadherent cells were removed by washing the well
with RPMI±HEPES and adherent cells were further incubated for 16
Gene Targeting in ES Cells hr in RPMI±HEPES supplemented with 1% autologous serum. Cell
W9.5 ES cells derived from a 129/Sv blastocyst, were grown on activation was performed in fresh medium containing LPS and
irradiated (3000 rads) primary embryonic fibroblasts (PMEFs) in ES rsCD14 at concentrations indicated in the text for 1 hr at 378C and
cell medium as described (KoÈ ntgen and Stewart, 1993). Cells (1 3 5% CO2. After removal of the supernatant, cells were lysed in 0.5
107) were electroporated in 0.8 ml of phosphate-buffered saline with ml of 10 mM HEPES (pH 7.9), 0.1% NP40, 1.5 mM MgCl2, 10 mM
25 mg of SalI-linearized targeting vector at 240 V, 500 mF in a Bio- KCl, 0.5 mM dithiothreitol, 0.5 mM PMSF (Kitchens et al., 1992) for
Rad Gene Pulser. Cells were transferred onto neor PMEF and selec- 10 min on a ice-water bath. After centrifugation at 750 3 g for 5
tion was started 16 hr later in ES cell medium supplemented with min at 408C, the supernatant was collected and assayed for cell-
G418 (350 mg/ml, GIBCO) and 5 days later with FIAU (0.2 mM, Oclas- associated IL-1b.
sen). To identify clones that exhibited homologous recombination,
DNA was extracted, digested with EcoRI, and subjected to Southern
Preparation of Bacteria and Injectionsblotting. An SstI±EcoRI fragment of the CD14 gene (Figure 1A), not
E. coli 0111:B4 were grown on tryptic soy broth (Difco) agar platescontained in the targeting vector, was used to detect mutant alleles
and single colonies were inoculated in tryptic soy broth. Bacteriathat give rise to a 3.1kb band, whereas the unmutated allele migrates
in midlogarithmic growth were collected, chilled on ice, and theas a 1.8 kb band (Figure 1B).
concentration was estimated from the absorbance at 620 nm using
a predetermined calibration curve. All concentrations of bacterialProduction of Germline Chimeras and Homozygous
suspensions were subsequently confirmed by viable bacterialMutant Mice
counts on agar plates. For injections, bacteria were washed onceOne of the targeted clones (E11) was expanded and injected into
in nonpyrogenic saline, and serial dilutions were prepared in saline.C57BL/6J blastocysts. The resulting chimeric animals were back-
CD14-deficient and control C57BL/6 mice were injected intraperito-crossed to C57BL/6J (Jackson Laboratories, Bar Harbor, Maine)
neally or in the tail vein with 0.2 ml of bacteria suspension. Survivalmice. Germline transmission was identified by Southern blot analy-
was monitored for 21 days.sis using the SstI±EcoRI fragment shown in Figure 1. Homozygous
CD14-negative mice were then produced by breeding heterozygous
Determination of Number of Bacterial Colony-Forminganimals.
Units in Blood and Organs of Infected MiceAssessment of the Biological Effects of LPS
Mice were infected intraperitoneally with E. coli 0111:B4. Mice werein CD14-Deficient Mice
sacrificed 7 hr after infection by CO2 inhalation, bled by heart punc-Mice (age-matched CD14-deficient and control C57BL/6J) were in-
ture, and their lungs were aseptically recovered and homogenized.jected intraperitoneally with 0.2 ml of a solution of LPS from Salmo-
Bacterial counts were determined by plating 10-fold serial dilutionsnella minnesota, wild-type (Sigma Chemical Company, St. Louis,
of blood or homogenized lungs on tryptic soy broth agar plates.Missouri) or from E. coli K235 (gift of Dr. S. Vogel, Department of
Results are represented as mean 6 SEM in each group. p < 0.05Microbiology and Immunology, Uniformed Services University of
(Mann-Whitney test).the Health Sciences, Bethesda, Maryland) in nonpyrogenic saline
(Baxter Healthcare Corporation, Deerfield, Illinois). This latter prepa-
ration of LPS contained less than 0.0008% of contaminating bacte- Cytokine Assays
rial proteins (Hogan and Vogel, 1988). For D-galactosamine sensiti- The concentration of TNFa in the serum of treated animals and in
zation, D-galactosamine (Sigma) was dissolved in nonpyrogenic culture supernatants was measured by cytotoxicity on WEHI-2T
saline and injected together with LPS in a total volume of 0.2 ml. cells as described (Haziot et al., 1993a) and PROBIT analysis (Wallis,
The LD100 of each LPS in each endotoxin shock model as well as 1991). IL-6 concentrations were determined by enzyme-linked im-
the dose of D-galactosamine to use (0.6 g/kg) was determined in munosorbent assay (ELISA) (Endogen, Boston, Massachusetts). The
prior experiments (data not shown). The condition and survival of lower limit of detection of TNFa in the bioassay was 0.05 pg/ml.
the injected mice was monitored daily for a period of 7 days. For The lower limit of detection of IL-6 was 5 pg/ml. IL-1b concentrations
determination of the serum concentration of cytokines, mice were were determined by ELISA (Genzyme, Cambridge, Massachusetts).
bled from the tail vein (50ml per mouse) at the indicated time intervals
and samples were analyzed as described below.
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